India's national government is busy laying plans to create a stand-alone ministry for pharmaceuticals and medical devices by the end of next year, increase regulation of online drugs and boost API production. But all is for naught if products cannot get out the door.
The U.S. Food and Drug Administration said violations of manufacturing protocols at Pan Drugs forced it to issue an "import alert" for human and animal medicines made by the Indian company.
China-based joint venture Shanghai Hutchison Pharmaceuticals will receive $105 million from the Shanghai government to vacate current factory space in the Putuo District as it prepares to open expanded facilities outside of the city.
India's Dr. Reddy's Laboratories has met a deadline to respond to a U.S. FDA warning letter on three of its plants under the scanner, but the contents are under wraps for now.
Hong Kong-listed 3SBio has moved to gain a controlling stake in biosimilar maker Shanghai CP Guojian Pharmaceutical, paying RMB1.4 billion ($213.3 million) in a deal that places it in the forefront of biotech in China.
Russia has a lot of purchasing muscle, but few sellers when it comes to pharmaceuticals, so the government has a plan to lure them with a vast increase in the products it buys from local makers. The nation's officials are focusing on the foreign drugmakers to set up production plants in Russia as one way to emerge from a string of recessions.
China has laid plans to change a commercial slur into a flattering term, at least for the quality of drugs it produces. The goal over the next 10 years or so is to make "Made in China" mean something other than cheap and shoddy work.
South Korea's Samsung BioLogics said last week it will spend at least $736 million to build a new manufacturing plant in Songdo, South Korea, that will have a 180,000-liter capacity when it's completed in 2018.
As with most corporate chiefs, Biocon's normally would be pleased with India's proposal to lower the nation's corporate tax rate to 25% from 30%. But, if it means eliminating tax exemptions for investments in research and development, Biocon is opposed.
China's Kelun Pharmaceutical has just opened a $50 million production plant in Almaty (formerly Alma-Ata), just across the border in Kazakhstan. Kelun Kazpharm executives told China's state-run Xinhua news agency the plant is responsible for 70% of the Kazakhstan market for intravenous medicines.